[
  {
    "ts": "2026-02-26T04:31:13+00:00",
    "headline": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
    "summary": "The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor",
    "url": "https://finance.yahoo.com/news/novo-nordisks-china-obesity-drug-043113091.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "6ca5da1b-6722-38a7-b2d7-398a6dedd5eb",
      "content": {
        "id": "6ca5da1b-6722-38a7-b2d7-398a6dedd5eb",
        "contentType": "STORY",
        "title": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
        "description": "",
        "summary": "The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor",
        "pubDate": "2026-02-26T04:31:13Z",
        "displayTime": "2026-02-26T04:31:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/2f4929ece0513781c2c8031526bc3e6e",
          "originalWidth": 1024,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/09hQCmD_hzreogiVWsq_UQ--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/2f4929ece0513781c2c8031526bc3e6e.cf.webp",
              "width": 1024,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VTi3w2RwIkJk2IUDUdfoJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2f4929ece0513781c2c8031526bc3e6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-china-obesity-drug-043113091.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-china-obesity-drug-043113091.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "3933.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T11:30:00+00:00",
    "headline": "Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforgl",
    "url": "https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-113000896.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "76f569b9-3207-3131-80ea-56f6e1233ab5",
      "content": {
        "id": "76f569b9-3207-3131-80ea-56f6e1233ab5",
        "contentType": "STORY",
        "title": "Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforgl",
        "pubDate": "2026-02-26T11:30:00Z",
        "displayTime": "2026-02-26T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-113000896.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-113000896.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T13:00:00+00:00",
    "headline": "Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer",
    "summary": "REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transit",
    "url": "https://finance.yahoo.com/news/soleno-therapeutics-announces-retirement-james-130000701.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "8b42b405-2ba2-39d8-816a-2250d81566a0",
      "content": {
        "id": "8b42b405-2ba2-39d8-816a-2250d81566a0",
        "contentType": "STORY",
        "title": "Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer",
        "description": "",
        "summary": "REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transit",
        "pubDate": "2026-02-26T13:00:00Z",
        "displayTime": "2026-02-26T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f08853057f613e1bc8d5445e6fb26887",
          "originalWidth": 276,
          "originalHeight": 110,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WOa9nxeL6Rj9HrMDWbz.Ww--~B/aD0xMTA7dz0yNzY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f08853057f613e1bc8d5445e6fb26887.cf.webp",
              "width": 276,
              "height": 110,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q4n3S8SASHFBkwCZ9UOGKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f08853057f613e1bc8d5445e6fb26887.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/soleno-therapeutics-announces-retirement-james-130000701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/soleno-therapeutics-announces-retirement-james-130000701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SLNO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T13:00:00+00:00",
    "headline": "OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response, Bringing Together Diverse Practice Types Across 39 States",
    "summary": "Denver, Colorado--(Newsfile Corp. - February 26, 2026) - The Obesity Medicine Association (OMA) is seeing strong early momentum for its Implementation into Practice Collaborative (IPC), a program designed to help clinicians strengthen obesity care through practical, evidence-based improvements in outpatient settings.The IPC is part of a multi-phase Quality Improvement (QI) initiative created specifically for OMA members. It was developed in collaboration with the Obesity Treatment Foundation...",
    "url": "https://finance.yahoo.com/news/otf-lilly-collaboration-registration-response-130000407.html",
    "source": "TMX Newsfile",
    "provider": "yfinance",
    "raw": {
      "id": "de92fedb-6ba9-3298-857c-237d588f45d3",
      "content": {
        "id": "de92fedb-6ba9-3298-857c-237d588f45d3",
        "contentType": "STORY",
        "title": "OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response, Bringing Together Diverse Practice Types Across 39 States",
        "description": "",
        "summary": "Denver, Colorado--(Newsfile Corp. - February 26, 2026) - The Obesity Medicine Association (OMA) is seeing strong early momentum for its Implementation into Practice Collaborative (IPC), a program designed to help clinicians strengthen obesity care through practical, evidence-based improvements in outpatient settings.The IPC is part of a multi-phase Quality Improvement (QI) initiative created specifically for OMA members. It was developed in collaboration with the Obesity Treatment Foundation...",
        "pubDate": "2026-02-26T13:00:00Z",
        "displayTime": "2026-02-26T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/newsfile_64/2212eba62280bcb6a7757ee1fb8dd9b1",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/f2W5wT7W0uD7fhtMRSO3Qw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/2212eba62280bcb6a7757ee1fb8dd9b1.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7vXOE.s4U6lB.BjtWMJC1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/2212eba62280bcb6a7757ee1fb8dd9b1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TMX Newsfile",
          "url": "https://www.newsfilecorp.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/otf-lilly-collaboration-registration-response-130000407.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/otf-lilly-collaboration-registration-response-130000407.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T12:37:00+00:00",
    "headline": "Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore",
    "summary": "How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.",
    "url": "https://www.fool.com/investing/2026/02/26/hims-hers-telehealth-growth-story-for-young-invest/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d22a9637-a22a-3620-ac36-3e1a9fceddf2",
      "content": {
        "id": "d22a9637-a22a-3620-ac36-3e1a9fceddf2",
        "contentType": "STORY",
        "title": "Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore",
        "description": "",
        "summary": "How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.",
        "pubDate": "2026-02-26T12:37:00Z",
        "displayTime": "2026-02-26T12:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/673e798a8b01d0179fcc2fdeaeff5d38",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Woman injecting self in arm with a GLP-1 injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L5zLfTXozWDxlHhpn2TUxg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/673e798a8b01d0179fcc2fdeaeff5d38.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HstI3TFCJeo.tm3LmT5hZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/673e798a8b01d0179fcc2fdeaeff5d38.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/26/hims-hers-telehealth-growth-story-for-young-invest/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hims-hers-telehealth-growth-story-123700542.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]